Asciminib (Scemblix) for chronic myeloid leukemia.
出版信息
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e107-e108. doi: 10.58347/tml.2023.1678g.
PMID:37339100
Abstract
摘要
相似文献
1
Asciminib (Scemblix) for chronic myeloid leukemia.阿伐替尼（Scemblix）用于治疗慢性粒细胞白血病。
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e107-e108. doi: 10.58347/tml.2023.1678g.
2
Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.阿斯科利尼布（Scemblix）：用于慢性期慢性髓性白血病伴或不伴T315I突变的三线治疗选择。
Am J Health Syst Pharm. 2023 Jan 5;80(2):36-43. doi: 10.1093/ajhp/zxac286.
3
Asciminib in chronic myeloid leukemia: many questions still remain to be answered.阿伐替尼治疗慢性髓性白血病：仍有许多问题有待解答。
Blood Cancer J. 2021 Apr 29;11(4):81. doi: 10.1038/s41408-021-00475-7.
4
Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.使用阿斯科利尼布和博舒替尼联合抑制BCR-ABL克服慢性髓性白血病患者的TKI耐药性。
Am J Hematol. 2021 Aug 1;96(8):E293-E295. doi: 10.1002/ajh.26231. Epub 2021 May 25.
5
Asciminib as a new option in the treatment of chronic myeloid leukemia.阿塞西尼布作为慢性粒细胞白血病治疗的新选择。
Future Oncol. 2021 Dec;17(36):5003-5005. doi: 10.2217/fon-2021-1174. Epub 2021 Nov 18.
6
Asciminib: First Approval.阿伐替尼：首次获批。
Drugs. 2022 Feb;82(2):219-226. doi: 10.1007/s40265-021-01662-3.
7
Breaking the mold: asciminib as a standard-of-care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting.打破常规：阿伐替尼作为一线慢性髓性白血病治疗武器库中的标准治疗药物。
Future Oncol. 2023 Mar;19(8):545-547. doi: 10.2217/fon-2023-0095. Epub 2023 Apr 11.
8
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.阿斯科利尼布治疗慢性髓性白血病患者在现实临床实践中的安全性和有效性。
Blood Cancer J. 2021 Feb 9;11(2):16. doi: 10.1038/s41408-021-00420-8.
9
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.真实世界分析 ASCIMINIB 在接受过波那替尼预处理的慢性髓性白血病患者中的安全性和疗效。
Ann Hematol. 2022 Oct;101(10):2263-2270. doi: 10.1007/s00277-022-04932-6. Epub 2022 Aug 23.
10
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.ASCIMINIB 的特异性，一种治疗慢性髓性白血病的潜在药物，作为一种豆蔻酰口袋结合的 ABL 抑制剂，并分析其与 BCR-ABL1 激酶突变形式的相互作用。
Leuk Res. 2020 Nov;98:106458. doi: 10.1016/j.leukres.2020.106458. Epub 2020 Sep 29.
Zotero 插件